Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)
Public ClinicalTrials.gov record NCT00910910. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and efficacy of lenalidomide as a first line therapy in treating patients with B-cell Chronic Lymphocytic Leukemia. This study will compare the effects (good and bad) of lenalidomide with chlorambucil.
Study identification
- NCT ID
- NCT00910910
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 450 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 65 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 13, 2009 (Actual)
- Primary completion
- Mar 31, 2014 (Actual)
- Completion
- May 9, 2018 (Actual)
- Last update posted
- Jul 9, 2019
2009 – 2018
United States locations
- U.S. sites
- 28
- U.S. states
- 16
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| California Cancer Associates for Research and Excellence cCARE | Escondido | California | 92025 | — |
| Innovative Clinical Research Institute | Whittier | California | 90603 | — |
| The Hospital of Central Connecticut | New Britain | Connecticut | 06050 | — |
| Cancer Center of Central Connecticut | Southington | Connecticut | 06489 | — |
| University Hematology Oncology Inc. | Centralia | Illinois | 62801 | — |
| North Chicago VA Medical Center | North Chicago | Illinois | 60064 | — |
| Medical Consultants, PC | Muncie | Indiana | 47303 | — |
| Floyd Memorial Cancer Center of Indiana, a division of Floyd Memorial Hospital and Health Services | New Albany | Indiana | 47150 | — |
| Purchase Cancer Group | Paducah | Kentucky | 42001 | — |
| University of Minnesota | Minneapolis | Minnesota | 55455-0392 | — |
| Saint Louis University Cancer Center | St Louis | Missouri | 63110 | — |
| Nevada Cancer Research Foundation | Las Vegas | Nevada | 89106 | — |
| Oncology and Hematology Associates, PA | Denville | New Jersey | 07834 | — |
| The Cancer Center, Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Somerset Hematology-Oncology Associates | Somerville | New Jersey | 08876 | — |
| Roswell Park Cancer Center | Buffalo | New York | 14263 | — |
| New York Medical College | Valhalla | New York | 10595 | — |
| Gabrail Cancer Center Research | Canton | Ohio | 44718 | — |
| Drexel University, College of Medicine | Philadelphia | Pennsylvania | 19102 | — |
| Pottstown Memorial Medical Center | Pottstown | Pennsylvania | 19464 | — |
| Berks Hematology-Oncology Associates | West Reading | Pennsylvania | 19611 | — |
| Geisinger Health System | Wilkes-Barre | Pennsylvania | 18711 | — |
| Charleston Hematology Oncology P.A. | Charleston | South Carolina | 29403 | — |
| South Carolina Cancer Specialists | Hilton Head Island | South Carolina | 29926 | — |
| Central Texas Veterans Health Care System | Temple | Texas | 76504 | — |
| Swedish Tumor Institute | Seattle | Washington | 98104 | — |
| Providence St. Mary Regional Cancer Center | Walla Walla | Washington | 99362 | — |
| Columbia St Marys Cancer Center | Milwaukee | Wisconsin | 53211 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 137 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00910910, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 9, 2019 · Synced Nov 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00910910 live on ClinicalTrials.gov.